YM BioSciences Inc. – Product Pipeline Review – Q4 2010

Date: November 1, 2010
Pages: 86
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: YD24E9EC5ABEN
Leaflet:

Download PDF Leaflet

YM BioSciences Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “YM BioSciences Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • YM BioSciences Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of YM BioSciences Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of YM BioSciences Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the YM BioSciences Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate YM BioSciences Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of YM BioSciences Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the YM BioSciences Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with YM BioSciences Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of YM BioSciences Inc. and identify potential opportunities in those areas.
YM BioSciences Inc. Snapshot
YM BioSciences Inc. Overview
Key Information
Key Facts
YM BioSciences Inc. – Research and Development Overview
Key Therapeutic Areas
YM BioSciences Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
YM BioSciences Inc. – Pipeline Products Glance
YM BioSciences Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
YM BioSciences Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
YM BioSciences Inc. – Drug Profiles
Nimotuzumab + Cisplatin + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
Nimotuzumab + Gemcitabine
  Product Description
  Mechanism of Action
  R&D Progress
Nimotuzumab + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
Nimotuzumab + Temozolomide + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
Tesmilifene
  Product Description
  Mechanism of Action
  R&D Progress
Theracim + Docetaxel + Carboplatin
  Product Description
  Mechanism of Action
  R&D Progress
AeroLEF
  Product Description
  Mechanism of Action
  R&D Progress
CYT-997
  Product Description
  Mechanism of Action
  R&D Progress
CYT997 + Carboplatin
  Product Description
  Mechanism of Action
  R&D Progress
CYT997@
  Product Description
  Mechanism of Action
  R&D Progress
Nimotuzumab
  Product Description
  Mechanism of Action
  R&D Progress
Nimotuzumab + Cisplatin + Vinorelbine + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
Nimotuzumab + Irinotecan
  Product Description
  Mechanism of Action
  R&D Progress
Nimotuzumab + Radiation Therapy
  Product Description
  Mechanism of Action
  R&D Progress
Tesmilifene
  Product Description
  Mechanism of Action
  R&D Progress
Tesmilifene + Anthracycline + Taxane
  Product Description
  Mechanism of Action
  R&D Progress
Theracim + 5-FU + Lipidol
  Product Description
  Mechanism of Action
  R&D Progress
CYT-997
  Product Description
  Mechanism of Action
  R&D Progress
CYT997@
  Product Description
  Mechanism of Action
  R&D Progress
Nimotuzumab
  Product Description
  Mechanism of Action
  R&D Progress
Oral CYT997
  Product Description
  Mechanism of Action
  R&D Progress
Theracim + Doxorubicin + Cyclophosphamide
  Product Description
  Mechanism of Action
  R&D Progress
Theracim + TACE
  Product Description
  Mechanism of Action
  R&D Progress
YM BioSciences Inc. – Pipeline Analysis
YM BioSciences Inc. – Pipeline Products by Therapeutic Class
YM BioSciences Inc. Pipeline Products By Target
YM BioSciences Inc. – Pipeline Products by Route of Administration
YM BioSciences Inc. – Pipeline Products by Molecule Type
YM BioSciences Inc. – Recent Pipeline Updates
YM BioSciences Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 06, 2010: YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response From Phase I/II Trial Of CYT387
Dec 06, 2010: YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response From Phase I/II Trial Of CYT387
Nov 18, 2010: YM BioSciences Expands Phase I/II Trial For JAK Inhibitor CYT387 In Patients With Myelofibrosis
Nov 18, 2010: YM BioSciences Expands Phase I/II Trial For JAK Inhibitor CYT387 In Patients With Myelofibrosis
Nov 08, 2010: YM BioSciences Reports Significant Response Rates In Anemia, Splenomegaly And Constitutional Symptoms From Phase I/II Trial Of CYT387 In Myelofibrosis
Nov 08, 2010: YM BioSciences Reports Significant Response Rates In Anemia, Splenomegaly And Constitutional Symptoms From Phase I/II Trial Of CYT387 In Myelofibrosis
Oct 01, 2010: YM Biosciences To Present Poster On CYT387 At European School Of Haematology International Conference
Oct 01, 2010: YM Biosciences To Present Poster On CYT387 At European School Of Haematology International Conference
Sep 08, 2010: YM BioSciences Announces Publication Of Positive Results Of CYT997 Phase I Study In British Journal Of Cancer
Aug 10, 2010: YM BioSciences Receives FDA Orphan Drug Designation For CYT387 For Treatment Of Myelofibrosis
Financial Deals Landscape
YM BioSciences Inc., Deals Volume Summary, 2004 to YTD 2010
YM BioSciences Inc., Deals Summary By Region, 2004 to YTD 2010
YM BioSciences Inc., Deals Summary, 2004 to YTD 2010
YM BioSciences Inc. Detailed Deal Summary
Merger
Cytopia Merges With YM BioSciences
Acquisition
YM BioSciences Acquires Delex Therapeutics
BBM Holdings Offers To Acquire YM BioSciences
Equity Offering
YM BioSciences Completes Registered Direct Offering Of $40 Million
YM BioSciences Completes Public Offering Of $16 Million
YM BioSciences Enters Into Collaboration Agreement With National Research Council Of Canada
CancerVax Enters Into An Agreement With CIMAB And YM Biosciences
Licensing Agreements
Daiichi Pharmaceutical Enters Into Licensing Agreement With CIMYM BioSciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

YM BioSciences Inc. – Pipeline by Therapy Area and Indication, 2010
YM BioSciences Inc. – Pipeline by Stage of Development, 2010
YM BioSciences Inc. – Monotherapy Products in Pipeline, 2010
YM BioSciences Inc. – Combination Treatment Modalities in Pipeline, 2010
YM BioSciences Inc. – Phase III, 2010
YM BioSciences Inc. - Phase II, 2010
YM BioSciences Inc. - Phase I, 2010
YM BioSciences Inc. - Pipeline By Therapeutic Class, 2010
YM BioSciences Inc. - Pipeline By Target, 2010
YM BioSciences Inc. – Pipeline By Route of Administration, 2010
YM BioSciences Inc. – Pipeline By Molecule Type, 2010
YM BioSciences Inc. – Recent Pipeline Updates, 2010
YM BioSciences Inc., Other Locations
YM BioSciences Inc., Subsidiaries
YM BioSciences Inc., Deals Summary, 2004 to YTD 2010
YM BioSciences Inc., Deals Summary by Region, 2004 to YTD 2010
YM BioSciences Inc., Deals Summary, 2004 to YTD 2010 70

LIST OF FIGURES

YM BioSciences Inc. – Pipeline by Therapy Area and Indication, 2010
YM BioSciences Inc. – Pipeline by Stage of Development, 2010
YM BioSciences Inc. – Monotherapy Products in Pipeline, 2010
YM BioSciences Inc. – Combination Treatment Modalities in Pipeline, 2010
YM BioSciences Inc. – Pipeline By Therapeutic Class, 2010
YM BioSciences Inc. - Pipeline By Target, 2010
YM BioSciences Inc. – Pipeline By Route of Administration, 2010
YM BioSciences Inc. – Pipeline By Molecule Type, 2010 53

Ask Your Question

YM BioSciences Inc. – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: